136 related articles for article (PubMed ID: 34890583)
1. Monitoring intracellular tacrolimus concentrations and its relationship with rejection in the early phase after renal transplantation.
Francke MI; Andrews LM; Lan Le H; van de Velde D; Dieterich M; Udomkarnjananun S; Clahsen-van Groningen MC; Baan CC; van Gelder T; de Winter BCM; Hesselink DA
Clin Biochem; 2022 Mar; 101():9-15. PubMed ID: 34890583
[TBL] [Abstract][Full Text] [Related]
2. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients.
Francke MI; Hesselink DA; Li Y; Koch BCP; de Wit LEA; van Schaik RHN; Yang L; Baan CC; van Gelder T; de Winter BCM
Br J Clin Pharmacol; 2021 Apr; 87(4):1918-1929. PubMed ID: 33025649
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
Lemaitre F; Antignac M; Fernandez C
Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
[TBL] [Abstract][Full Text] [Related]
4. Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Ther Drug Monit; 2019 Aug; 41(4):528-532. PubMed ID: 31259882
[TBL] [Abstract][Full Text] [Related]
5. Association Between the Intracellular Tacrolimus Concentration in CD3 + T Lymphocytes and CD14 + Monocytes and Acute Kidney Transplant Rejection.
Udomkarnjananun S; Francke MI; Dieterich M; van de Velde D; Verhoeven JGHP; Boer K; Clahsen-Van Groningen MC; De Winter BCM; Baan CC; Hesselink DA
Ther Drug Monit; 2022 Oct; 44(5):625-632. PubMed ID: 35358111
[TBL] [Abstract][Full Text] [Related]
6. Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients.
Arreola-Guerra JM; Alberú J; Chew-Wong A; Macias DM; Hernández-Rosales J; Zuñiga-Macías L; Delgadillo-Castañeda R; Ricalde-Ríos G; Haro-Alcalde F; Villafán-Bernal JR; Ramos-Medellín CL; Reyes-Acevedo R
Clin Transplant; 2019 Dec; 33(12):e13749. PubMed ID: 31691354
[TBL] [Abstract][Full Text] [Related]
7. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study.
Capron A; Lerut J; Latinne D; Rahier J; Haufroid V; Wallemacq P
Transpl Int; 2012 Jan; 25(1):41-7. PubMed ID: 21981711
[TBL] [Abstract][Full Text] [Related]
8. Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function.
Han SS; Yang SH; Kim MC; Cho JY; Min SI; Lee JP; Kim DK; Ha J; Kim YS
PLoS One; 2016; 11(4):e0153491. PubMed ID: 27082871
[TBL] [Abstract][Full Text] [Related]
9. Pretransplant Tacrolimus Dose Requirements Predict Early Posttransplant Dose Requirements in Blood Group AB0-Incompatible Kidney Transplant Recipients.
Shuker N; de Man FM; de Weerd AE; van Agteren M; Weimar W; Betjes MG; van Gelder T; Hesselink DA
Ther Drug Monit; 2016 Apr; 38(2):217-22. PubMed ID: 26630539
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
[TBL] [Abstract][Full Text] [Related]
11. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
12. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection.
Capron A; Lerut J; Verbaandert C; Mathys J; Ciccarelli O; Vanbinst R; Roggen F; De Reyck C; Lemaire J; Wallemacq PE
Ther Drug Monit; 2007 Jun; 29(3):340-8. PubMed ID: 17529892
[TBL] [Abstract][Full Text] [Related]
13. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
14. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
[TBL] [Abstract][Full Text] [Related]
16. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.
Velickovic-Radovanovic R; Mikov M; Catic-Djordjevic A; Stefanovic N; Mitic B; Paunovic G; Cvetkovic T
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):95-102. PubMed ID: 24596067
[TBL] [Abstract][Full Text] [Related]
17. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
18. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
Kuypers DR; Vanrenterghem Y
Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
[TBL] [Abstract][Full Text] [Related]
19. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells.
Lemaitre F; Blanchet B; Latournerie M; Antignac M; Houssel-Debry P; Verdier MC; Dermu M; Camus C; Le Priol J; Roussel M; Zheng Y; Fillatre P; Curis E; Bellissant E; Boudjema K; Fernandez C
Clin Biochem; 2015 Apr; 48(6):406-11. PubMed ID: 25562187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
